anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides analogues of  alpha -1-antichymotrypsin having amino acid substitutions at positon 358.  alpha -1-antichymotrypsin analogues having amino acid substitutions at positions 356-361 and analogues having amino acid substitutions at positions 356-361 wherein the amino acid at position 358 is substituted are also within the scope of the invention. These analogues exhibit chymase inhibitory activity. Also provided are novel  alpha -1-antichymotrypsins having an N-terminal extension of methionine-alanine-serine or alanine-serine. Expression vectors for the production of  alpha -1-antichymotrypsins are also provided. The present invention also provides host cells and cell cultures capable of expressing analogues of  alpha -1-antichymotrypsin, as well as protein preparations from the host cells. Methods of producing and using the analogues of  alpha -1-antichymotrypsin to inhibit chymase activity are also provided.
<P>PROBLEM TO BE SOLVED: To provide a method for efficiently producing a low-molecular weight hyaluronic acid.  <P>SOLUTION: The method involves carrying out malt/organic acid fermentation in a state of a raw material hyaluronic acid containing a mineral. Concretely, the mineral is added to the raw material hyaluronic acid having about 500,000-1,200,000 molecular weight, and the resultant mixture is sterilized by steaming with a prescribed amount of purified water. One or mixture of two or more kinds of Aspergillus oryzae, yeast, citric acid bacteria, lactic bacteria, acetic acid bacteria, and the Aspergillus oryzae or the like containing a fiber-splitting enzyme is added to the sterilized mixture and fermented. One or a mixture of two or more kinds of organic acids having carboxy groups such as citric acid, lactic acid, tartaric acid and malic acid is added to the fermented hyaluronic acid, and the resultant mixture is matured by holding the mixture at a prescribed temperature. The resultant product hyaluronic acid is filtered and extracted. The low-molecular weight hyaluronic acid having about 2,000 molecular weight is efficiently produced by the method.  <P>COPYRIGHT: (C)2007,JPO&INPIT
OBJECTIVE: Musculoskeletal disorders frequently affect postmenopausal women. This study aims to compare muscle disorders between women according to the type of experienced menopause: premature (PM) or normal age of menopause (NAM).
METHODS: This was a cross-sectional study conducted in nine Latin American countries in which late postmenopausal women (55 to 70 years) were surveyed with a general questionnaire, the Menopause Rating Scale (MRS: item #4 exploring musculoskeletal discomfort), and strength, assistance with walking, rising from a chair, climbing stairs, and falling questionnaire (risk of sarcopenia).
RESULTS: A total of 644 women were included: 468 who had NAM, and 176 who had PM (116 spontaneous and 60 surgical). The overall mean age of the participants was 60.9 ± 4.2 years. Women who had PM experienced more musculoskeletal discomfort (33.5% vs 20.9%, P < 0.001) and a higher likelihood of sarcopenia (35.2% vs 19.9%, P < 0.001) than women who had a NAM. Women who had surgical PM exhibited a higher prevalence of severe musculoskeletal discomfort (46.7% vs 29.3%, P < 0.02) and a higher likelihood of sarcopenia (45.0% vs 27.6%, P < 0.02) than women who had a NAM. After adjusting for covariates (age, body mass index, menopausal hormone therapy use, physical activity, education, cigarette consumption, use of antidepressants, sexual activity, comorbidities, and having a partner), our logistic regression model determined that spontaneous PM was not associated with higher odds of musculoskeletal discomfort and higher odds of sarcopenia. On the other hand, women who had surgical PM were more likely to experience musculoskeletal discomforts (odds ratio: 2.26; 95% confidence interval: 1.22-4.17) and higher odds for sarcopenia (odds ratio: 2.05; 95% confidence interval: 1.16-3.65) as compared to women who experienced a NAM.
CONCLUSIONS: Women experiencing surgical PM have a higher likelihood of developing muscle disorders. This underscores the potential significance of hormonal levels in influencing musculoskeletal health during postmenopause.
BACKGROUND: Emergency general surgery conditions are common, costly, and highly morbid. The proportion of excess morbidity due to variation in health systems and processes of care is poorly understood. We constructed a collaborative quality initiative for emergency general surgery to investigate the emergency general surgery care provided and guide process improvements.
METHODS: We collected data at 10 hospitals from July 2019 to December 2022. Five cohorts were defined: acute appendicitis, acute gallbladder disease, small bowel obstruction, emergency laparotomy, and overall aggregate. Processes and inpatient outcomes investigated included operative versus nonoperative management, mortality, morbidity (mortality and/or complication), readmissions, and length of stay. Multivariable risk adjustment accounted for variations in demographic, comorbid, anatomic, and disease traits.
RESULTS: Of the 19,956 emergency general surgery patients, 56.8% were female and 82.8% were White, and the mean (SD) age was 53.3 (20.8) years. After accounting for patient and disease factors, the adjusted aggregate mortality rate was 3.5% (95% confidence interval [CI], 3.2-3.7), morbidity rate was 27.6% (95% CI, 27.0-28.3), and the readmission rate was 15.1% (95% CI, 14.6-15.6). Operative management varied between hospitals from 70.9% to 96.9% for acute appendicitis and 19.8% to 79.4% for small bowel obstruction. Significant differences in outcomes between hospitals were observed with high- and low-outlier performers identified after risk adjustment in the overall cohort for mortality, morbidity, and readmissions. The use of a Gastrografin challenge in patients with a small bowel obstruction ranged from 10.7% to 61.4% of patients. In patients who underwent initial nonoperative management of acute cholecystitis, 51.5% had a cholecystostomy tube placed. The cholecystostomy tube placement rate ranged from 23.5% to 62.1% across hospitals.
CONCLUSION: A multihospital emergency general surgery collaborative reveals high morbidity with substantial variability in processes and outcomes among hospitals. A targeted collaborative quality improvement effort can identify outliers in emergency general surgery care and may provide a mechanism to optimize outcomes.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
Fecal filtrate transfer (FFT) is emerging as a safer alternative to traditional fecal microbiota transplantation (FMT) - particularly in the context of necrotizing enterocolitis (NEC), a severe gastrointestinal condition affecting preterm infants. Using a preterm piglet model, FFT has demonstrated superiority over FMT in safety and NEC prevention. Since FFT is virtually devoid of bacteria, prokaryotic viruses (bacteriophages) are assumed to mediate the beneficial effects. However, this assumption remains unproven. To address this gap, we separated virus-like particles (30 kDa to 0.45 µm) of donor feces from the residual postbiotic fluid. We then compared clinical and gut microbiota responses to these fractions with the parent FFT solution after transferring them to NEC-susceptible preterm piglets. Virome transfer was equally effective as FFT in reducing the severity of NEC-like pathology. The bacterial compositional data corroborated clinical findings as virome transfer reduced the relative abundance of several NEC-associated pathogens e.g. Klebsiella pneumoniae and Clostridium perfringens. Virome transfer diversified gut viral communities with concomitant constraining effects on the bacterial composition. Unexpectedly, virome transfer, but not residual postbiotic fluid, led to earlier diarrhea. While diarrhea may be a minor concern in human infants, future work should identify ways of eliminating this side effect without losing treatment efficacy.
Compounds of the general formula (1), salts thereof and their hydrates. (1) In the formula, each of R, R, R and R independently is a hydrogen atom, etc. R is an optionally substituted phenyl, etc. R is an optionally substituted C aryl, etc. Each of Z and Z independently is a hydrogen atom. They are useful as a therapeutic agent and/or preventive for diseases caused by clot formation, being safer, and have appropriate physicochemical stability.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

1\. Use aseptic technique for the preparation of CYTALUX infusion solution.

2\. Only use 5% Dextrose Injection for dilution. Do not use other diluents due to incompatibility [see Warnings and Precautions ( 5.4)] . 

3\. CYTALUX vials should be stored and thawed in the original carton protected from light.

a. Thaw at room temperature between 20° to 25°C (68° to 77°F) for at least 60 minutes or under refrigerated conditions between 2° to 8°C (36° to 46°F) for at least 6 hours. When thawed under refrigerated conditions, allow the vial to stand at room temperature for 15 minutes before dilution.

b. Once thawed, an individual CYTALUX vial may be stored at room temperature between 20° to 25°C (68° to 77°F) for a maximum single period of 24 hours or under refrigerated conditions between 2° to 8°C (36° to 46°F) for a maximum single period of up to 30 days, prior to preparation for infusion.

c. If CYTALUX vial is not used within the maximum single period at either room temperature or under refrigerated conditions the vial may be refrozen up to one time.

4\. Hand shake or vortex the thawed CYTALUX vial for 60 seconds.

5\. Withdraw the calculated volume of CYTALUX for a dose of 0.025 mg/kg. Discard any unused portion in the vial.

6\. Add into a 250 mL of 5% Dextrose Injection, USP bag.

7\. Gently swirl the bag by hand for 1 minute to mix the solution.

8\. Visually inspect the infusion bag. The solution should be light blue/green to clear in color and should not contain any visible particulate matter.

9\. Protect the infusion bag from light using a light-blocking cover during infusion and storage.

10\. If not immediately used, store the diluted CYTALUX infusion solution in a refrigerator at 2 o to 8 oC (36 o to 46 oF) for not more than 24 hours. Once the bag is removed from refrigeration, infusion must be completed within 3 hours.
A hot-melt extruded composition is disclosed that includes about 20-80 % wt. of a plant- derived phenolic material; about 20-85 % wt. of one or more edible or bioerodible excipients; about 0-40 % wt. of a surface active material; about 0-40 % wt. of an oral absorption enhancer; and about 0-10 % wt. of one or more pharmaceutical or food grade additives. The composition has been hot-melt extruded at a temperature substantially below the melting point of the plant- derived phenolic material to produce a hot-melt extruded composition wherein substantial degradation of the plant-derived phenolic material has not occurred.
DACOS is a national large- scale, longitudinal, multi-center, prospective, cohort study of natural person aged 35 to 75. The baseline survey and the follow-up surveys will be conducted in 5 areas covering the eastern, northern, western, southern and middle parts of China. In this study 100,000 natural person will be regularly followed up for 5 years(visited once a year), with the loss rate ≤15%. Three parts will be carried in the form of interview, physical examination and biological sample collection. During the interview, the investigators plan to do some questionnaires to learn participants' demographic characteristics, life style, disease history, healthy condition(EQ-5D-5L, SDS,), cognition state(AD-8, MMSE, MoCA) and the results of TCM syndrome differentiation(Score of Dampness syndrome and TCM constitution scale). All biological specimens (including blood, feces, urine, saliva and tongue coating) will be collected and stored in the biological resource center until researchers request their use. With the building up of this cohort, the researchers will analyze the causality between dampness syndrome and specific chronic diseases such as diabetes, coronary heart disease, cancer, dementia and so on.
This study seeks to assess the impact of chiropractic on cognition. Participants must be between 18 and 35 years of age. Within the past six months individuals may not participate if they have had any broken bones, accidents, or surgeries to their spine. Additionally, participants cannot have any mental disabilities, be pregnant, or have other conditions of the spine such as bone mineral loss.

Patients will receive a chiropractic exam and will be randomized to a sham (simulated chiropractic adjustment) or chiropractic adjustment intervention group. Prior to receiving either the sham or chiropractic adjustment, the participants will sit in front of a computer screen and will be asked to follow instructions and press a button on a keypad. There will be three different types of computer assessments that will take approximately fifteen minutes total. After the computer assessments the participant will receive either the sham or chiropractic adjustment. The chiropractic adjustment and the sham will both utilize a handheld instrument called an Activator. After the adjustment or sham the participant will take the computer assessments again. The total time this may take is ninety minutes.
A novel computer gaming hand exercise regimen has been designed for people with Rheumatoid arthritis (RA) or Osteo arthritis (OA) affecting the hands. The design allows a broad range of common objects of daily life to be seamlessly transformed into 'therapeutic' input devices by instrumenting with a small motion sense mouse. Based on individual abilities and treatment needs, objects are selected to train specific fine/ gross dexterous functions. The object manipulations (therapeutic exercises) are then used to control and play any commercially available computer game, making practice challenging and engaging.

The study is of six weeks duration comparing the computer gaming and conventional hand exercises in thirty people diagnosed with RA or OA affecting the hands. The investigators hypothesize that the game based exercises will improve hand function and reduce pain/stiffness and be feasible compared to the conventional hand exercises.A mixed-effect repeated measures analysis of variance will be conducted to test pre to post treatment outcomes. This will be the first study to evaluate the therapeutic effects and feasibility of the computer gaming hand exercise regimen in people with RA or OA.
INTRODUCTION: Severe traumatic brain injury (TBI) increases the risk of early posttraumatic seizures (EPTS). Guidelines suggest the use of prophylactic antiseizure agents, including levetiracetam. This study aims to evaluate the feasibility of using levetiracetam dosing based on Glasgow Comas Scale (GCS) scores with higher doses used for more severe TBI.
METHODS: Patients 6 months to 18 years old admitted to Penn State Hershey Children's Hospital (PSHCH) with a TBI who received levetiracetam for EPTS prophylaxis with at least one documented GCS score were included. Patients were divided into two cohorts: before and after implementation of the pediatric TBI Cerner PowerPlan at PSHCH which standardized levetiracetam dosing based on GCS scores. Primary outcome was appropriate dosing of levetiracetam based on GCS. Secondary outcomes included seizure occurrence and adverse effects.
RESULTS: Eighty-five patients were included: 42 in the pre-PowerPlan group and 43 in the post-PowerPlan group. Overall, 46 (54%) patients received the appropriate levetiracetam dose based on GCS (pre-PowerPlan, n = 19 [45%] vs. post-PowerPlan n = 27 [63%], p = 0.104). Sixty-four percent of severe TBI patients received appropriate levetiracetam dosing after implantation of the PowerPlan compared with 28% prior to the PowerPlan (p = 0.039). Three patients in each group experienced a seizure while on levetiracetam. Two patients experienced agitation and somnolence attributed to levetiracetam.
CONCLUSION: Levetiracetam dosing based on GCS scores in pediatric TBI patients is a novel approach, and dosing accuracy may be increased with use of a PowerPlan. Additional large-scale studies are needed to evaluate efficacy and safety of this approach prior to widespread implementation.
Discrete capsules, each consisting of a single, substantially p water-insoluble core entity surrounded by an encapsulating wall consisting of a plurality of hydrophilic colloid materials, at least one of which is gellable, are prepared by forming a dispersion of the core material in an aqueous dispersion of the colloid material, causing complex coacervation of the said colloid material some of which coats the core particles, effecting decoacervation (i.e. redispersion) of the remnant colloid material, adding supplementary colloid material, and again causing complex coacervation whereby a further coating of colloid material is deposited on to the first coating.  The coating may subsequently be gelled, e.g. by chilling and, if desired, hardened or plasticized.  The core material may be liquid, e.g. an animal, vegetable, mineral or partly or wholly synthetic oil, a solid or a solid dispersed in a liquid and it may be a food, drug, dye, chemical reactant, perfume, flavouring, electrostatic or magnetic material.  Specified colloid materials are gelatin, gum arabic and ethylene-maleic anhydride copolymer (molecular weight about 1000 to 2000 and 50,000 to 70,000).  It is preferred that the latterly deposited colloid "complex" is similar but not identical to that deposited initially, e.g. the first may consist of the copolymer of molecular weight 1000 to 2000, gelatin and gum arabic and the second may differ in that the copolymer is of molecular weight 50,000-70,000.  Coacervation and decoacervation may be effected by known methods, e.g. variation of pH or temperature, the process being carried out under continuous stirring at a temperature above the gel point of the gelable colloid. Specification 757,100 is referred to.
Provided are mechanisms and processes for directional signal fencing for medical schedule management. According to various examples, a system is provided which comprises a first sensor module, which includes a directional transceiver configured to transmit a first wireless signal directed toward a location within a medical examination room such that the location is within a first coverage area. A second sensor module includes a directional transceiver configured to transmit a second wireless signal directed toward the location such that the location is within a second coverage area. The first and second coverage areas overlap at a signal overlap area, which surrounds the location. The first and second sensor modules connect to a device corresponding to a physician within the signal overlap area. The duration of the connection between the device and the sensor modules is used to track the presence of the physician in the medical examination room.
The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration.  Preferred compounds include 2-[18F]FACBC and 2-[18F]FMACBC. The labeled amino acid compounds of the invention are useful as imaging agents in detecting and/or monitoring tumors in a subject by PET or SPECT.
An isocaloric product (made with maltodextrin) in powdered form with flavoring. Product will be added to 180-200 mL of warm water prior to consumption.
The invention discloses a marine streptomyces and tunicamycin compound and a preparation method thereof. Streptomyces maritima (Streptomyces sp.) SCSIO 15077 was deposited in China general microbiological culture Collection center (CGMCC) on 23.1.2017 at the address: the collection number of the microbial research institute of the Chinese academy of sciences, No. 3 Xilu-Beijing province, Chaoyang, and the collection number is: CGMCC No. 13649. The fermentation culture of the marine Streptomyces sp SCSIO 15077 can prepare a new compound tunicamycin E as shown in a formula (I). The invention provides a biological preparation method for the production and preparation of tunicamycin, and has wide application prospect.
Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
Systems and methods of embodiments comprise receiving in real-time data of parameters representing an entity. Micro plots are generated, and each micro plot comprises a plot of the data for a corresponding time period of a multitude of time periods. Each time period is cyclical. A model plot is generated to include the micro plots plotted chronologically according to the time periods. The model plot comprises a continuous helix. A prediction of a state of the entity is generated using characteristics of the model plot.
A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient. They are a white, opaque capsule and administered orally.
Studies have pointed out racial differences in the outcome of conventional filtration surgery. Glaucoma drainage implants have been found to do well in Asian eyes but no randomized controlled trial is available to support this claim. Objectives: It is the aim of this study to compare the effectiveness and safety of combined phacoemulsification, posterior chamber intraocular lens implantation , trabeculectomy (phacotrabeculectomy) versus phacoemulsification, intraocular lens implantation and glaucoma drainage device(phacotube) in the early and intermediate control of intraocular pressure(IOP) in patients with primary open angle and angle closure glaucoma. The secondary objective is to look into the post-operative complications encountered in phacotrabeculectomy and phacotube including the additional interventions (laser suture lysis, bleb needling, antimetabolite injections, etc.) applied in both procedures being studied Study Design. Randomized controlled trial. Methods. A total of 50 Asian subjects, 21 years old and above diagnosed with primary open/angle closure glaucoma, inadequately controlled by laser and medical treatment, with significant cataract and no previous eye surgery will be randomized to two types of combined procedures, phacotrabeculectomy and phacotube. Primary outcome measure is intraocular pressure and secondary outcome measures will be visual acuity, anterior chamber depth, visual field stability or progression, glaucoma medication requirement, operative and post-operative complications and additional, secondary interventions(e.g. laser suture lysis, bleb needling, 5-FU injections, anterior chamber reformation). All subjects will be followed up for a period of 1 year.This trial may define the role of GDI as a primary surgical option for Asian patients and the first randomized clinical trial in Asia to compare two combined procedures for glaucoma and cataract namely phacotrabeculectomy and phaco-glaucoma drainage implant surgery.﷡